Servier Symphogen A/S

Servier Symphogen serves as a Centre of Excellence for discovery and development of Antibody Therapeutics as a fully owned subsidiary to Les Laboratoires Servier. Servier Symphogen is applying its highly efficient antibody platform in the discovery and early development of new and differentiated antibody therapeutics through innovative research technologies. Servier Symphogen was founded in 2000 and became part of the Servier Group in June 2020 as a part of Servier's commitment to improving patients' health within oncology and neurology through antibody therapeutics. On September 1, 2025, the company changed its name from Symphogen to Servier Symphogen to emphasize its affiliation with Servier. Antibody therapeutics have revolutionized treatment of multiple diseases, among them cancer, our mission is to leverage our 25 years of experience in the field to find new first in class and best in class antibody therapeutics of innovative modalities.